Dr. Ramzi Khamis is a Clinical Senior Lecturer in Cardiology and a consultant cardiologist, with a subpecilaity in interventional cardiology. He is a Fellowship endowed British Heart Foundation clinician scientist in Cardiovascular Medicine. Dr. Khamis undertakes both his clinical and research work at the Hammersmith Hospital Campus.
Dr. Khamis was trained in general cardiology, interventional cardiology and translational cardiovascular medicine at Imperial College and its affiliated hospitals. Dr. Khamis completed his interventional cardiology fellowships at the Hammersmith Hospital. He was awarded his consultant level accreditation (CCT) in both G(I)M and cardiology from the Royal College Of Physicians, and PhD from Imperial college London in 2014. Dr. Khamis is also a fellow of the European Society of Cardiology (FESC). Dr. Khamis first graduated from Bristol in 2000, and undertook his House Officer training at Bristol and Bath followed by Emergency Medicine training in Leeds, and then by General Internal Medicine training as part of the Barts and the London Medical SHO training scheme in London. Dr. Khamis also taught physiology at Bristol University as a tutor in 2002.
He was awarded and completed a highly competitive Academic Clinical Fellowship in Cardiology, encompassing both clinical and academic training, funded by the National Institute for Health Research (NIHR) at the National Heart and Lung Institute, as well as competitive Fellowships in Interventional Cardiology at the Hammersmith Hospital London in 2009-10 and 2013-14. He was also awarded a Wellcome Trust/ GSK Clinical Research Fellowship in Translational Medicine, undertaking his PhD under the Supervision of Profs Haskard and Matthews.
His research interests include the development of a multimodality imaging strategy for the detection of vulnerable plaque in atherosclerosis, developing novel biomarkers in cardiovascular risk assessment and the understanding the role of antibodies in atherosclerosis.
In 2014, Dr Khamis was the winner of the British Cardiovascular Society Young Research Worker of the Year Award and a finalist at the American College of Cardiology Young Investigator of the Year Award. He was also British Atherosclerosis Society Young Investigator of the Year finalist 2013 and the winner of the British Atherosclerosis Binks travel award (Harvard Medical School) 2013.
Dr. Khamis group encompasses both clinicians and scientists focusing on the targeting of oxidised LDL in atherosclerosis using interventional and non interventional modalities such as near infra-red fluorescence (NIRF) imaging and positron emission tomography (PET). He also undertakes research to explore the mechanistic link between the humeral immune system and atherosclerosis. Dr. Khamis' group are developing various serological tests to better risk stratify cardiac risk in patients and populations.
Hartley A, Haskard D, Khamis R, 2019, Oxidized LDL and anti-oxidized LDL antibodies in atherosclerosis – Novel insights and future directions in diagnosis and therapy,, Trends in Cardiovascular Medicine, Vol:29, ISSN:1050-1738, Pages:22-26
et al., 2018, IgM anti-malondialdehyde low density lipoprotein antibody levels indicate coronary heart disease and necrotic core characteristics in the Nordic Diltiazem (NORDIL) study and the Integrated Imaging and Biomarker Study 3 (IBIS-3)., Ebiomedicine, Vol:36, ISSN:2352-3964, Pages:63-72
et al., 2019, THE ROLE OF HIGH-SENSITIVITY C-REACTIVE PROTEIN IN PREDICTING MORTALITY BEYOND TROPONIN IN OVER 100,000 PATIENTS WITH SUSPECTED ACUTE CORONARY SYNDROME (NIHR HEALTH INFORMATICS COLLABORATIVE CRP-RISK STUDY), Annual Conference of the British-Cardiovascular-Society (BCS) - Digital Health Revolution, BMJ PUBLISHING GROUP, Pages:A120-A121, ISSN:1355-6037
et al., 2019, HSCRP PREDICTS MORTALITY BEYOND TROPONIN IN 102,337 PATIENTS WITH SUSPECTED ACUTE CORONARY SYNDROME IN THE UK NATIONAL INSTITUTE FOR HEALTH RESEARCH CRP-RISK STUDY, 68th Annual Scientific Session and Expo of the American-College-of-Cardiology (ACC), ELSEVIER SCIENCE INC, Pages:10-10, ISSN:0735-1097
et al., 2018, OXIDISED LDL AND ANTI-OXIDISED LDL ANTIBODIES ARE REDUCED BY LIPOPROTEIN APHERESIS IN A RANDOMISED CONTROLLED TRIAL ON PATIENTS WITH REFRACTORY ANGINA AND ELEVATED LIPOPROTEIN(A), 86th Congress of the European-Atherosclerosis-Society (EAS), ELSEVIER IRELAND LTD, Pages:E31-E32, ISSN:0021-9150